licensing opportunity oncology new class

Popular

Description

I have two promising novel classes of anticancer drugs with first in class attributes available for in licensing.

The Non Proteolytic Proteasome Inhibitor demonstrated a Proteasome inhibition through a novel mechanism/target. This compound is currently at the lead generation stage.

POC : In-vitro cytotoxicactivity on human cancer cells

A screening platform could be discussed as well

Please contact

Jean-Charles Brosse

e-mail :

jcharlesbrosse@aol.com

jcharlesbrosse@gmail.com

mobile : +33607832134 

 

More details

Name Description
Pharma licensing Out-licensing (offer)

Ad details

Ad ID : 676

Advertiser details

Contact Advertiser

Add comment

 
 

Contact form

Sorry, you need to register or login first.

What's wrong with this ad?

Sorry, you need to register or login first.

Add to favourites

Sorry, you need to register or login first.

Advert search

Recent adverts

A pharmaceutical company from Turkey, selling...
1109 Views
Wuxi Griffin Pharmaceuticals Co. Ltd. is...
676 Views
A pharmaceutical company from Turkey, selling...
860 Views
Active substance formulated into Tivortin®  –...
1041 Views
1. An entirely new combination. An original...
652 Views
I’m a representative of Parafarm (Penza,...
1657 Views
We offer a dossier for registration of...
1440 Views